What drives the recent move in LTIM.NS stock?

The immediate driver is a Reuters-reported **$100.00m** medtech contract. The deal improves revenue visibility and supports higher-margin digital services. Investors should monitor deal conversions and the April 2026 earnings date for confirmation.

What is Meyka AI's short and long forecast for LTIM.NS stock?

Meyka AI's model projects a monthly price of **INR 4,334.78** and a yearly price of **INR 6,352.24**. That implies a near-term downside of **-12.60%** and a yearly upside of **+28.09%**, model-based and not guaranteed.

Is LTIM.NS stock fairly valued by common metrics?

LTIMindtree trades at PE **30.13** and PB **6.04**, above sector averages, reflecting growth expectations. Strong margins and ROE offset the premium, but valuation remains a key risk for investors.

How should traders manage risk in LTIM.NS stock pre-market?

Use layered entries near technical support and set tight stops below the lower Bollinger band at **INR 4,680.05**. Keep position sizes aligned with volatility and reassess around earnings and deal announcements.

IN Stocks

PRE MARKET: LTIM.NS (LTIMindtree) NSE Feb 2026 $100.00m deal: model +28.09%

ByHuzaifa Zahoor February 24, 2026February 24, 2026

The LTIM.NS stock opens pre-market after news that LTIMindtree won a $100.00m contract with a European medtech firm, a deal that supports near-term revenue visibility. At INR 4,959.50 the share trades below its 50-day average of INR 5,878.82, leaving valuation and momentum questions for investors. We examine fundamentals, technicals, and model forecasts to show how the medtech order and current metrics shape the LTIM.NS stock outlook for Indian market traders and global clients.